Published • loading... • Updated
New Clinical Study Highlights Durable, Robust Immune Response of Participants Using Turkey Tail Paired with Agarikon Mushroom Mycelium
The FoTv mushroom mycelium combination was well tolerated and linked to immune biomarker support in healthy adults during a six-month study including vaccination timing.
- On March 3, 2026, Fungi Perfecti, LLC announced University of California San Diego published a Phase I/II trial in BMC Immunology evaluating FoTv.
- The trial's design used a short dosing window at the time of vaccination, with participants receiving FoTv for four consecutive days and followed for a six‑month period.
- The product FoTv combines Fomitopsis officinalis and Trametes versicolor and was tested in healthy adult participants, the study reported.
- The trial reported FoTv was well tolerated, and researchers at UCSD measured immune‑related biomarkers across participants.
- Publicity from Fungi Perfecti framed the peer-review‑ed findings that the paper concluded results suggest FoTv supports select immune biomarkers in healthy individuals, announced on March 3, 2026.
Insights by Ground AI
12 Articles
12 Articles
Montana Standard+11 Reposted by 11 other sources
New Clinical Study Highlights Durable, Robust Immune Response of Participants Using Turkey Tail Paired with Agarikon Mushroom Mycelium
OLYMPIA, Wash., March 3, 2026 /PRNewswire/ -- A recently published Phase I/II clinical trial in the peer-reviewed journal BMC Immunology, and announced by University of California San Diego (UCSD), evaluated a combination of Fomitopsis officinalis (Agarikon) and Trametes versicolor (Turkey…
Coverage Details
Total News Sources12
Leaning Left1Leaning Right0Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium
